Double-blind cross-over study of the effect of Namenda [memantine] on short term memory and attention in patients with mild to moderate traumatic brain injury, protocol NAM-MD-44

Trial Profile

Double-blind cross-over study of the effect of Namenda [memantine] on short term memory and attention in patients with mild to moderate traumatic brain injury, protocol NAM-MD-44

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Brain injuries
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2011 Planned end date changed from 1 Jan 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 09 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Jun 2010 Planned end date changed from 1 Sep 2009 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top